MORRISTOWN

Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference

Retrieved on: 
Thursday, May 9, 2024
Bezafibrate, Gastrointestinal disease, Learning, Intercept, Abstract, Aspartic acid, Primary biliary cholangitis, Fibrosis, Intercept Pharmaceuticals, Therapy, Senior, Liver, Obeticholic acid, DDW, Hepatology, PBC, Risk, Head, Pharmaceutical industry

MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abstracts on primary biliary cholangitis (PBC) will be presented at Digestive Disease Week® (DDW) 2024.

Key Points: 
  • MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abstracts on primary biliary cholangitis (PBC) will be presented at Digestive Disease Week® (DDW) 2024.
  • “These data, along with new analyses from our landmark Phase 3 POISE trial, showcase our continued commitment to helping improve the lives of people living with PBC.
  • A full list of sessions at DDW 2024 is available at www.ddw.org .
  • Attendees of DDW can visit Intercept at booths #3741 and #3828 throughout the meeting.

Viz.ai® Announces Three New Studies Supporting Viz HCM™ Module for the Detection and Management of Suspected Hypertrophic Cardiomyopathy

Retrieved on: 
Wednesday, April 3, 2024
Health, Technology, Hospitals, Health Technology, Software, Artificial Intelligence, Cardiology, Deep learning, FACC, Harvard Medical School, Machine learning, Cone Health Women's Hospital, PPV, Innovation, Algorithm, Artificiality, Assistant, Disease, Associate, Patient, Atlantic Health System, Triage, Salem Hospital, AI, Viz, American College, Massachusetts General Hospital, HCM, Hospital, Hypertrophic cardiomyopathy, Senior counsel, Sports cardiology, Hypertrophy, Medical director, Probability, FDA, ACC, ECG, Mass, Medical imaging

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care.
  • The Viz HCM module is the first and only AI algorithm cleared by the FDA for HCM.
  • The study found that Viz HCM performance in suspected HCM detection was consistent across various racial backgrounds with a sensitivity of 68.4% and specificity of 99.1%.
  • This validates the effectiveness of relevance score sorting for prioritizing higher probability HCM-positive patients identified by deep-learning algorithms analyzing ECG data.

Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC

Retrieved on: 
Thursday, February 29, 2024
Therapy, Senior, Ursodeoxycholic acid, Pamlab, New Drug Application, FDA, Food, Shanda, PDUFA, Regulatory affairs, Database, PBC, Communication, Hepatology, Cirrhosis, Intercept, Primary biliary cholangitis, Patient, UDCA, Obeticholic acid, Intercept Pharmaceuticals, Advisory Committee, Pharmaceutical industry

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 15, 2024.

Key Points: 
  • The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 15, 2024.
  • In this communication, the agency informed Intercept that they are planning to hold an Advisory Committee meeting to discuss the application.
  • The precedent-setting sNDA for Ocaliva is intended to satisfy the post-marketing requirements to confirm a clinical benefit in patients with PBC.
  • Intercept and Alfasigma remain committed to supporting people living with PBC and look forward to advancing discussions with the agency.

BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

Retrieved on: 
Tuesday, February 27, 2024
Human services, Oxygen, Gelsolin, Incidence, Sepsis, ICU, Inflammation, Randomness, Safety, Quality of life, Șaeș, Causality, Drive, Administration, Infection, Nursing care plan, Therapy, Patient, Standard of care, Trauma, Efficacy, Mortality, Plasma, Pharmaceutical industry

Approximately 80 sites in the US, Canada, UK and the EU, including Belgium, France, Italy, Germany, Netherlands, Spain and others will conduct the study.

Key Points: 
  • Approximately 80 sites in the US, Canada, UK and the EU, including Belgium, France, Italy, Germany, Netherlands, Spain and others will conduct the study.
  • The planned primary outcomes are all-cause mortality at Day 28 between treatment groups and incidence, causality, and severity of SAEs in rhu-pGSN vs placebo treatment.
  • Breathing becomes difficult and patients require oxygen, mechanical ventilation and extensive critical care resources, placing a significant burden on the healthcare system.
  • In the U.S. alone, ARDS affects over 700,000 patients per year or roughly 10% of all ICU admissions.

Mill Creek Named 2023 Elite 5 Multifamily Company by Kingsley

Retrieved on: 
Wednesday, February 21, 2024
Index, Database, BOCA, Tier, Elite, Management

BOCA RATON, Fla., Feb. 21, 2024 /PRNewswire/ -- Mill Creek Residential, a leading developer, owner-operator and investment manager specializing in premier rental housing across the U.S., today announced it has been named as one of the Elite 5 Multifamily Companies by the Kingsley Excellence Awards program for the second consecutive year. 

Key Points: 
  • Additionally, 10 Mill Creek communities were included in Kingsley's Top 100 Multifamily Properties for 2023.
  • "We are honored and extremely grateful to receive this esteemed recognition from Kingsley," said Bill MacDonald , chairman, CEO and president of Mill Creek Residential.
  • Kingsley Top 100 and Elite 5 winners must exceed Grace Hill's Kingsley Index for overall satisfaction in the prior year.
  • Following Modera Cherry Creek on the Top 100 Multifamily Properties list were four additional communities in the top 50: Modera Woodbridge (Woodbridge, N.J.) at No.

Private Advisor Group Announces Strategic New Headquarters Office in Morristown, NJ and Expansion in the Carolinas

Retrieved on: 
Friday, February 2, 2024
Suite, Growth, Financial services

MORRISTOWN, N.J., Feb. 2, 2024 /PRNewswire/ -- Private Advisor Group , one of the largest and fastest-growing independent wealth management firms in the country*, proudly announces significant milestones in its ongoing strategic expansion.

Key Points: 
  • MORRISTOWN, N.J., Feb. 2, 2024 /PRNewswire/ -- Private Advisor Group , one of the largest and fastest-growing independent wealth management firms in the country*, proudly announces significant milestones in its ongoing strategic expansion.
  • Private Advisor Group has relocated its headquarters to a state-of-the-art office space at 305 Madison Ave. in Morristown, NJ.
  • Additionally, the space is sublet to local financial advisors affiliated with Private Advisor Group, creating a collaborative and dynamic environment.
  • "The historic setting of our new office adds a unique dimension to our presence in the Carolinas," said Frank Smith, CEO of Private Advisor Group.

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023

Retrieved on: 
Monday, November 13, 2023
UDCA, Primary biliary cholangitis, Hypertension, ALP, Research and development, OCA, Obeticholic acid, Hepatology, ALT, Intercept Pharmaceuticals, Aes, Ursodeoxycholic acid, PBC, AASLD, Intercept, PPAR, FXR, Serum, Data analysis, Alanine transaminase, FDA, Liver, Alkaline phosphatase, Bezafibrate, GGT, Therapy, University, Development, Biomarker, Itch, Magnetic resonance, Safety, Pharmaceutical industry, Fused quartz, Medicine, Boston, Patient

These data will be presented on Monday, November 13, 2023, at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® in Boston (poster #5019-C).

Key Points: 
  • These data will be presented on Monday, November 13, 2023, at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® in Boston (poster #5019-C).
  • One severe TEAE (pruritus, OCA5/B100 IR) occurred in Study 214; no TEAEs led to study discontinuation in Study 214.
  • The Company expects to have the necessary data from the OCA-bezafibrate combination program to submit a request in 2023 for an End-of-Phase 2 meeting with the FDA.
  • These data include analyses from both Phase 2 studies, in addition to Phase 1 and preclinical data.

Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023

Retrieved on: 
Friday, November 10, 2023
PBC, Liver, ALP, GGT, Therapy, Poster, OCA, Hepatology, Intercept Pharmaceuticals, Survival

MORRISTOWN, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly-owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced new data from a sub-analysis of the landmark Phase 3 POISE trial evaluating the impact of obeticholic acid (OCA) on achievement of gamma-glutamyl transferase (GGT)

Key Points: 
  • This analysis suggests OCA’s potential to reduce GGT, in addition to the well-known effects on ALP levels, below the biochemical thresholds that are prognostic for worsening clinical outcomes.
  • These data will be presented on Monday, November 13, 2023, at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® in Boston.
  • Elevated GGT in the setting of elevated ALP and other liver enzyme abnormalities is a marker for hepatobiliary disorder.
  • The goal of this sub-analysis was to evaluate the proportion of patients receiving OCA who achieved and sustained GGT

ArtPride New Jersey Unveils Annual Holiday Guide Featuring Upcoming Winter Events Throughout the Garden State

Retrieved on: 
Tuesday, November 28, 2023
Garden State, Princeton University, Magic, Tuna, New Jersey Ballet, Cape May Stage, A Christmas Carol, Mayo Performing Arts Center, NJPAC, Partnership, Garden, McCarter, Museum, Martial arts, Film industry, Tourism, Entertainment, Nightclub, BURLINGTON

BURLINGTON, N.J., Nov. 28, 2023 /PRNewswire-PRWeb/ -- ArtPride New Jersey, the state's largest arts service organization, today announced the release of its annual Winter Holidays Guide, featuring upcoming in-person events throughout the Garden State. The guide curates festive holiday experiences from theaters, museums, dance companies and art centers. The initiative is dedicated to increasing awareness and participation in the arts in New Jersey.

Key Points: 
  • Discover Jersey Arts spotlights live theater, art and musical performances happening this holiday season
    BURLINGTON, N.J., Nov. 28, 2023 /PRNewswire-PRWeb/ -- ArtPride New Jersey , the state's largest arts service organization, today announced the release of its annual Winter Holidays Guide, featuring upcoming in-person events throughout the Garden State.
  • "The Winter Holidays Guide is an essential resource for celebrating the holiday season with artistic flair.
  • "The Winter Holidays Guide is an essential resource for celebrating the holiday season with artistic flair.
  • The holiday guide features events in northern, southern and central New Jersey, including:
    Morristown: " New Jersey Ballet's Nutcracker With New Jersey Symphony " showcases eye-popping special effects, brilliant dancing, and glorious costumes during this holiday classic.

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

Retrieved on: 
Wednesday, November 8, 2023
Bezafibrate, Gastroenterology, Obeticholic acid, FDA, Delaware General Corporation Law, Food, Tax, Medication, Intercept Pharmaceuticals, Intercept, Liver, Acquisition, PBC, Primary biliary cholangitis, Autoimmune disease, USD, Hepatology, Patient, DNA, Food and Drug Administration, Holding company, Pharmaceutical industry, Pamlab

BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.

Key Points: 
  • BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.
  • As a result of the transaction, Intercept has become a wholly owned subsidiary of Alfasigma, and the common stock of Intercept has ceased to be traded on the NASDAQ Stock Market.
  • Stefano Golinelli, Chairman of Alfasigma, commented: “At Alfasigma, the passion we have for Pharmaceuticals is in our DNA - and a driver for our ambitious international growth plans.
  • Francesco Balestrieri, CEO of Alfasigma, added: “Today, we complete a transformational acquisition which strongly aligns with our strategy of building a solid presence in gastroenterology and hepatology, Alfasigma’s core business areas.